In summary, our results provide evidence that a selective Wip1 inhibitor causes targeted antiproliferative effects on TP53 wild-type neuroblastoma with potential additive benefit when combined with DNA damaging chemotherapies, currently used to treat patients with this disease. The gene discussed is PPM1D; the disease is neuroblastoma.